GHRS vs. TWST, VCEL, MOR, MLTX, MRUS, CPRX, EWTX, ARWR, AMRX, and MIRM
Should you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Twist Bioscience (TWST), Vericel (VCEL), MorphoSys (MOR), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Catalyst Pharmaceuticals (CPRX), Edgewise Therapeutics (EWTX), Arrowhead Pharmaceuticals (ARWR), Amneal Pharmaceuticals (AMRX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.
GH Research vs.
Twist Bioscience (NASDAQ:TWST) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, community ranking, analyst recommendations, valuation, institutional ownership and dividends.
Twist Bioscience received 76 more outperform votes than GH Research when rated by MarketBeat users. However, 75.00% of users gave GH Research an outperform vote while only 59.20% of users gave Twist Bioscience an outperform vote.
GH Research has a net margin of 0.00% compared to Twist Bioscience's net margin of -59.76%. GH Research's return on equity of -20.29% beat Twist Bioscience's return on equity.
Twist Bioscience has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.
GH Research has lower revenue, but higher earnings than Twist Bioscience. GH Research is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
56.9% of GH Research shares are owned by institutional investors. 3.0% of Twist Bioscience shares are owned by insiders. Comparatively, 41.6% of GH Research shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Twist Bioscience currently has a consensus price target of $53.80, indicating a potential upside of 19.34%. GH Research has a consensus price target of $30.25, indicating a potential upside of 116.30%. Given GH Research's stronger consensus rating and higher probable upside, analysts plainly believe GH Research is more favorable than Twist Bioscience.
In the previous week, GH Research had 2 more articles in the media than Twist Bioscience. MarketBeat recorded 4 mentions for GH Research and 2 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.63 beat GH Research's score of 0.51 indicating that Twist Bioscience is being referred to more favorably in the media.
Summary
GH Research beats Twist Bioscience on 11 of the 16 factors compared between the two stocks.
Get GH Research News Delivered to You Automatically
Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GH Research Competitors List
Related Companies and Tools
This page (NASDAQ:GHRS) was last updated on 2/21/2025 by MarketBeat.com Staff
Free GHRS Stock Alerts